Patents Assigned to OncoMed Pharmaceuticals, Inc.
-
Patent number: 8455623Abstract: Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof.Type: GrantFiled: May 21, 2009Date of Patent: June 4, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Edward Thein Htun Van Der Horst, Aaron Ken Sato
-
Publication number: 20130121993Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.Type: ApplicationFiled: February 29, 2012Publication date: May 16, 2013Applicant: ONCOMED PHARMACEUTICALS, INC.Inventor: AUSTIN GURNEY
-
Publication number: 20130115206Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.Type: ApplicationFiled: February 29, 2012Publication date: May 9, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Aaron K. Sato
-
Patent number: 8435513Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: July 8, 2009Date of Patent: May 7, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
-
Patent number: 8425903Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: May 15, 2012Date of Patent: April 23, 2013Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Publication number: 20130095116Abstract: The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate ?-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins, such as antibodies that specifically bind RSPO1, RSPO2, and/or RSPO3 and inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.Type: ApplicationFiled: July 13, 2012Publication date: April 18, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Fumiko Takada Axelrod, Timothy Charles Hoey, Cecile Chartier-Courtaud
-
Patent number: 8420885Abstract: A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.Type: GrantFiled: September 23, 2011Date of Patent: April 16, 2013Assignees: The Regents of the University of Michigan, Oncomed Pharmaceuticals, Inc.Inventors: Michael F. Clarke, Scott J. Dylla, Sanjeev Satyal
-
Publication number: 20130089560Abstract: The present invention provides bone morphogenetic protein receptor (BMPR) binding agents, such as antibodies, and compositions comprising said binding agents. The binding agents are useful to treat diseases such as cancer.Type: ApplicationFiled: March 17, 2011Publication date: April 11, 2013Applicant: OncoMed Pharmaceuticals IncInventors: Cecile Chartier-Courtaud, Austin L. Gurney
-
Publication number: 20130045209Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human Wnt(s) are provided. A conserved domain within Wnt that is suitable as a target for anti-cancer agents is also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: ApplicationFiled: January 12, 2011Publication date: February 21, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventor: Austin L. Gurney
-
Publication number: 20130034551Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.Type: ApplicationFiled: January 12, 2011Publication date: February 7, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Sanjeev SATYAL, Satyajit MITRA, Austin GURNEY
-
Publication number: 20130030155Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: ApplicationFiled: May 15, 2012Publication date: January 31, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: John A. LEWICKI, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
-
Patent number: 8324361Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.Type: GrantFiled: March 15, 2010Date of Patent: December 4, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Publication number: 20120301489Abstract: Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer.Type: ApplicationFiled: November 19, 2010Publication date: November 29, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Aaron Ken Sato, Alexandra Lazetic, Zhimin Ji
-
Publication number: 20120288496Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: May 15, 2012Publication date: November 15, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Publication number: 20120263721Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.Type: ApplicationFiled: October 18, 2010Publication date: October 18, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Robert Joseph Stagg, Steven Eugene Benner
-
Publication number: 20120213786Abstract: The present invention relates to Notch1 binding agents and methods of using the agents for treating diseases, such as hematologic cancers. The present invention provides antibodies that specifically bind to a non-ligand binding membrane proximal region of the extracellular domain of human Notch1. The present invention further provides methods of using agents that inhibit Notch1 activity for treating cancer. Also described are methods of treating hematologic cancers comprising administering a therapeutically effective amount of a binding agent or antibody of the present invention to a subject having a hematologic cancer such as T-cell lymphoblastic leukemia.Type: ApplicationFiled: January 13, 2011Publication date: August 23, 2012Applicant: OncoMed Pharmaceuticals, Inc.Inventor: Edward Thein Htun VAN DER HORST
-
Patent number: 8226943Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: GrantFiled: July 8, 2009Date of Patent: July 24, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Patent number: 8206713Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: GrantFiled: January 20, 2011Date of Patent: June 26, 2012Assignee: Oncomed Pharmaceuticals, Inc.Inventors: John A. Lewicki, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
-
Patent number: 8158757Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.Type: GrantFiled: July 2, 2008Date of Patent: April 17, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. Gurney, Aaron K. Sato
-
Patent number: 8158758Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.Type: GrantFiled: July 2, 2008Date of Patent: April 17, 2012Assignee: OncoMed Pharmaceuticals, Inc.Inventor: Austin Gurney